We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Panel Improves Diagnosis of Candida in Pediatric Patients

By LabMedica International staff writers
Posted on 15 Jul 2015
Print article
In an investigational study of pediatric patients, a Candida test panel provided accurate, fast diagnosis with only 2 mL of blood.

Rapid detection of Candida enables faster initiation of targeted treatment and can reduce a patient's length of hospitalization by almost 9 days. A rapid negative result can prevent unnecessary administration of antimicrobials as well as prevent or reduce antimicrobial resistance.

T2 Biosystems, Inc. (Lexington, MA, USA) presented results from an investigational study evaluating its T2Candida Panel in pediatric patients at the 2015 American Society for Microbiology (ASM) general meeting in New Orleans (LA, USA). The study included 15 confirmed candidemia patients 5–12 years of age. The data presented showed that in each of the 15 patient samples, T2Candida was able to accurately identify the species in 3–5 hours, compared to 2–6 days for blood culture. For this study a manual pipetting protocol was adapted to enable detection from just 2 mL of blood compared to the 3 mL currently required for the standard loading procedure.

"Fast and accurate results have been a challenge to obtain in pediatric patients suspected of sepsis due to the volume of blood required by current diagnostic procedures," said Prof. Camille Hamula, Icahn School of Medicine, Mount Sinai Hospital, "This new loading procedure maintains the high accuracy and fast results of the T2Candida Panel but with lower sample volume, which could have an important impact on the lives of young patients at risk of sepsis." "We are encouraged by these findings demonstrating that our T2Candida Panel was able to provide accurate results from lower blood volumes, which is critical in the pediatric patient population," said John McDonough, T2 Biosystems president and CEO.

T2Candida Panel, the first sepsis pathogen diagnostic that provides species-specific results in 3–5 hours without need for blood culture, was cleared for marketing by the US Food and Drug Administration (FDA) in September 2014. T2Candida Panel performance was established in adult subjects; performance in neonates, infants, and pediatric patients has not been established.

Related Links:

T2 Biosystems
ASM 2015 presentation of study results


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Analyzer 2.0 with remote test results access enhances collaboration across the healthcare system (Photo courtesy of QIAGEN)

Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access

QIAGEN (Venlo, the Netherlands) has released the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade. This represents a significant advancement from the initial QIAstat-Dx Analyzer 1.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The RedDrop One blood collection device has received 510(k) clearance from the U.S. FDA for prescription use (Photo courtesy of RedDrop Dx)

Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy

The discomfort associated with traditional blood draws leads to a significant issue: approximately 30% of diagnostic tests prescribed by physicians are never completed by patients. This avoidance is often... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.